independent source (Haque et al., 2005) . The pharmacology education was inadequate to prepare the future physician to combat this situation (Rahman, 1995; Rahman, 1999; Begum et al., 1999) and consequently, the misleading claims appearing in the printed promotional literature worsened the situation (Islam and Farah, 2007) . Present study was conducted in this backdrop, adherence of promotional literature to existing Code of Pharmaceutical Marketing Practice was evaluated along with scientific authenticity of the promotional claims of some selected medicinal products.
Materials and Methods
Pharmaceutical promotional materials were collected from selected inpatient and out patient departments of BSMMU. Large designed and labelled envelopes were provided to the clinical staffs (medical officers, residents and postgraduate students) to store the promotional materials which they receive from representatives of pharmaceutical companies during one week of study period (study weeks were chosen with 6 working days in each). One similar envelope was also kept with one faculty member of the respective departments for the same purpose and period. Next week, all promotional materials stored in the envelope were collected by the researcher.
Pharmaceutical promotional literature were screened and separated from other promotional materials. Then only promotional literature were evaluated for the rest of the study.
Step I: Total number of promotional literature of each department was counted.
Step II: Promotional literature were categorized into allopathic, Unani, Ayurvedic, herbal, cosmetics, medical device and other.
Step III: Promotional literature other than allopathic drugs were excluded.
Step IV: Allopathic products were categorized and promotional literature other than 'full advertisement' were excluded.
Step V: Promotional literature of 'full advertisement' of few products were excluded from the review process due to absence of information about those products in the latest edition of BDNF or BNF.
Step VI:
Quality of those selected 'full advertisements' was then assessed in two phases.
Evaluation of adherence
Adherence of all collected promotional literature to the Code of Pharmaceutical Marketing Practices (CPMP) was assessed by a checklist. Among the mentioned parameters of CPMP, presence of selected parameters such as indications, side effects, precautions, contraindications and cited references were assessed. Total 440 promotional literature were evaluated in this phase.
Evaluation of authenticity

Authenticity of the claims (if present)
Later on, promotional claims were evaluated for authenticity. 10 new products (medicinal products those were only present in 4 th edition of Bangladesh National Formulary but absent in 3 rd edition of Bangladesh National Formulary) were selected from each department for evaluation of promotional claims. When the number of new products was more than 10, then the products were randomly included to be studied. If promotional literature of the same new medicine was found in other department, only one was included to avoid repetition in order to increase product variability. Medicinal products having multiple promotional literature circulated by different manufacturers were included for separate evaluation. Total 73 promotional literature were evaluated in this phase.
Promotional claims were compared with cited references of promotional literature, original innovator's product monograph and also with independent sources of drug information such as BDNF, reference book, "Martindale: The Complete Drug Reference" and/or websites of different regulatory bodies. In case of any inaccessibility of full paper, their abstracts were retrieved.
If a product was absent in 4 th edition of BDNF, then latest available edition (67 th ) of BNF was used as an alternative of similar nature. Latest available online edition (36 th ) of "Martindale: The complete drug reference" was used as a reference book because of its updated regulatory viewpoint, which was suitable for this study. Among the websites of regulatory bodies', website of Therapeutic Goods Administration (TGA) of Australia was selected for this study. If, any product was not approved in Australia but approved in Bangladesh, in those cases, websites of Medicine and Healthcare products Regulatory Agency (MHRA) of United Kingdom, Food and Drug Administration (FDA) of United States of America and European Medicines Agency (EMA) of European Union were used for evaluation process. Promotional claims were categorized into true, exaggerated, ambiguous, controversial and false on the basis of research findings, regulatory status and availability of products. Table I showed that the printed promotional literature were 77.6, 12.7, 5.0, 2.7, 0.5, 0.12 and 1.2% for allopathic, cosmetic, herbal, Unani, Ayurvedic, device and others respectively. All reviewed promotional literature (100.0%) contained name of the active ingredient, trade name and detail information about license holder. Active ingredient per dosage formulation, approved dosage schedule, route of administration was mentioned in 88.9, 66.4 and 86.6% of the reviewed promotional literature respectively (Table II) (Table III) . Table IV showed that 1,020 references were mentioned in 440 promotional literature, of which scientific article, commercial online information sources, data on file, regulatory body approval data, product mono-graph and textbook/reference book were cited as reference in 747 (73.3%), 158 (15.5%), 43 (4.2%), 29 (2.9%), 27 (2.7%) and 16 (1.6%).
Results
Adherence to code of pharmaceutical marketing practice
Out of 1020 references mentioned in the literature, retrieval was possible in 512 (50.2%) cases. Among these retrieved documents, 454, 29, 22, 6 and 1 references were from scientific article, online commercial sources, product monograph and textbook/ reference book and regulatory body approval data respectively. None of the reference from data on file was retrievable (Table V) .
Total 153 promotional claims were present in 73 promotional literature of which 98 (64.1%), 46 (30.1%), 4 (2.6%), 1/153 (0.7%), 3 (2.5%) and 1 (0.7%) were about efficacy, safety, cost, pharmaceutical property, pharmacokinetic property and others respectively (Table VI) . Out of 153 claims, 112 (73.2%), 7 (4.6%), 9 (5.9%), 4 (2.6%) and 21 (13.7%) were found to be true, ambiguous, exaggerated, controversial and false respectively (Table VII) .
Discussion
Promotional literature are considered as the most widely used pharmaceutical promotional tools, though claimed to be educational materials, the authenticity of provided information is questionable (Avorn et al., 1982) . Interactions of physician-pharmaceutical industry have been commenced with the motto of 'keeping modern in medicine' (Greene and Podolsky, 2009 ).
In the present study, name of the active ingredient with trade name along with detail information about license holder was mentioned in all promotional literature like previous studies (Jadav et al., 2014; Michael, 2015) . However, essential prescribing information like therapeutic indication, side effects, precautions and contraindications were present in promotional literature in varying degree (88.2, 40.0, 33.9 and 38.9%), which corresponds with some of the previous researches (Alam et al., 2009; Khakhkhar et al., 2013) . High proportion of exaggerations in case of indications and/or omissions of safety information correspond with a study conducted in Bangladesh (Haque et al., 2005) . Scientific articles were cited as references in large proportion (73.3%) of materials, but half of them could not be retrieved, which matches with earlier studies conducted in India (Mali et al., 2010; Randhawa et al., 2015) . Similar to Mali et al. (2010) , proportion (24.8%) of promotional materials found to cite references from commercial online information sources. Like previous similar studies (Mali et al., 2010; Saibhavana et al., 2015) , most (64.1%) of the promotional claims were focused on efficacy of the product rather than safety or cost. Presence of true claim (73.2%) was less than that of another similar study (Rohra et al., 2006) . Prevalence of exaggerations (5.9%) corresponds with a study conducted in a developing country (Randhawa et al., 2015) . Similar to some previous studies (Rohra et al., 2006; Murthy and Krishnamurthy, 2010) , a small proportion of promotional claims were either ambiguous (4.6%) or controversial (2.6%) or false (13.7%). The quality of promotional literature indicates the necessity of caution on the part of physicians while interpreting the claims mentioned in these. The policy makers and educators may find these findings interesting to take required regulatory measure.
Conclusion
The printed promotional materials contain exaggerated claims and other deviations from the standard. 
